Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing patent infringement litigation.

In 2022, Alnylam filed a patent infringement lawsuit against Moderna, claiming it violated a newly obtained patent.

The claim is over mRNA technology Moderna used in developing its COVID-19 vaccine, Alnylam says. 

In the lawsuits filed in U.S. District Court in Delaware, Alnylam said its newly granted patent covers the vaccine’s messenger-RNA delivery systems and violates an Alnylam patent on lipid nanoparticle (LNP) technology for delivering genetic material into human cells. 

However, after the ...

Full story available on Benzinga.com